Pathstone Family Office’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $80K | Buy |
17,390
+2,466
| +17% | +$11.3K | ﹤0.01% | 1601 |
|
|
2023
Q2 | $96.4K | Sell |
14,924
-902
| -6% | -$5.83K | ﹤0.01% | 1188 |
|
|
2023
Q1 | $119K | Sell |
15,826
-19,350
| -55% | -$146K | ﹤0.01% | 1121 |
|
|
2022
Q4 | $356K | Sell |
35,176
-724
| -2% | -$7.33K | ﹤0.01% | 1209 |
|
|
2022
Q3 | $356K | Buy |
35,900
+17,205
| +92% | +$170K | ﹤0.01% | 1178 |
|
|
2022
Q2 | $199K | Buy |
18,695
+4,177
| +29% | +$44.5K | ﹤0.01% | 962 |
|
|
2022
Q1 | $142K | Buy |
14,518
+1,425
| +11% | +$13.9K | ﹤0.01% | 913 |
|
|
2021
Q4 | $187K | Buy |
13,093
+1,100
| +9% | +$15.7K | ﹤0.01% | 843 |
|
|
2021
Q3 | $240K | Buy |
+11,993
| New | +$240K | 0.01% | 749 |
|